T3 Pharma Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 15

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $26.5M

  • Investors
  • 9

T3 Pharma General Information

Description

Developer of immuno-oncology therapies designed to treat cancer patients. The company's therapies use a proprietary protein delivery platform by repurposing the bacterial type III secretion (T3S) system to treat solid cancer tumors, enabling healthcare providers to improve the lives of the patients and cure them.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Care of Swiss TPH Kreuzstrasse 2
  • Allschwil
  • 4123 Basel
  • Switzerland
+41 000000000

T3 Pharma Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

T3 Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 22-Jul-2020 $26.5M 000.00 Completed Generating Revenue
5. Early Stage VC 26-Sep-2019 000.00 000.00 000.00 Completed Generating Revenue
4. Grant 28-May-2019 000.00 00.000 Completed Generating Revenue
3. Accelerator/Incubator 30-Jan-2018 00000 00.000 Completed Generating Revenue
2. Angel (individual) 28-Nov-2016 $2.91M $2.91M 00.000 Completed Pre-Clinical Trials
1. Grant $2.01M Completed Pre-Clinical Trials
To view T3 Pharma’s complete valuation and funding history, request access »

T3 Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B Preference 00,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
To view T3 Pharma’s complete cap table history, request access »

T3 Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of immuno-oncology therapies designed to treat cancer patients. The company's therapies use a proprietary prot
Drug Discovery
Basel, Switzerland
15 As of 2022
000.00
0000000000 0 000.00

000000

ulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mo
0000 000000000
Rockville, MD
0 As of 0000
000.00
0000000000 0 000.00

000000

olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui of
0000 000000000
Houston, TX
0 As of 0000
0000
0000000000 0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

T3 Pharma Competitors (60)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytImmune Sciences Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
000000 Venture Capital-Backed Houston, TX 0 0000 0000000000 0 0000
0000000 0000000000 Formerly VC-backed Boston, MA 0 00000 000000000 00000
00000000 Venture Capital-Backed Geneva, Switzerland 00 000.00 00000000000 000.00
00000000 Venture Capital-Backed Watertown, MA 00 0000 00000000000 0000
You’re viewing 5 of 60 competitors. Get the full list »

T3 Pharma Executive Team (5)

Name Title Board Seat Contact Info
Simon Ittig Ph.D Co-Founder & Chief Executive Officer
Christoph Kasper Ph.D Co-Founder & Chief Scientific Officer
Marlise Amstutz Ph.D Co-Founder & Executive Director of Microbiology
Claire Barton Chief Medical Officer
Roger Meier Co-Founder
To view T3 Pharma’s complete executive team members history, request access »

T3 Pharma Board Members (3)

Name Representing Role Since
Frank Kalkbrenner Ph.D Boehringer Ingelheim Venture Fund Board Member 000 0000
Helmut Kessmann Ph.D T3 Pharma Board Member 000 0000
Olvier Valdenaire Ph.D Self Chairman 000 0000
To view T3 Pharma’s complete board members history, request access »

T3 Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

T3 Pharma Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Wille Finance Family Office Minority 000 0000 000000 0
Boehringer Ingelheim Venture Fund Venture Capital Minority 000 0000 000000 0
Reference Capital (Switzerland) Venture Capital Minority 000 0000 000000 0
W A de Vigier Foundation Other 000 0000 000000 0
BaseLaunch Accelerator/Incubator 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »